Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma-Reference-Cited by-同舟云学术

Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma

Published:2001-02 Issue:2 Volume:12 Page:187-192
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Bonetti A.,Zaninelli M.,Leone R.,Franceschi T.,Fraccon A.P.,Pasini F.,Sabbioni R.,Cetto G.L.,Sich D.,Brienza S.,Howell S.B.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/12/2/187/19479113/12-2-187.pdf

Reference36 articles.

1. Oxaliplatin, tetraplatin, cisplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute’s Anticancer Drug Screen Panel;Rixe;Biochem Pharmacol,1996

2. Oxaliplatin: A review of preclinical and clinical studies;Raymond;Ann Oncol,1998

3. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers;Becouarn;J Clin Oncol,1999

4. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study;Diaz Rubio;Ann Oncol,1998

5. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines;Machover;Ann Oncol,1996

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estimating the distribution of ratio of paired event times in phase II oncology trials;Statistics in Medicine;2022-12-27

2. Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis;Cancers;2020-11-04

3. Phase II trial design with growth modulation index as the primary endpoint;Pharmaceutical Statistics;2018-11-20

4. Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology;Computational and Mathematical Methods in Medicine;2018

5. Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling;BioMed Research International;2016